Dr Andrew N Schiff

KANDO id: 5648

Bio

Dr Schiff joined Fund I in September of 1999 and has served as a Managing Partner since 2002. Prior to joining Fund I, Dr Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine. Dr Schiff currently serves as a director of ARMGO Pharma Inc, Dynova Laboratories Inc, Planet Technologies Inc, Sirion Therapeutics Inc, SkinMedica Inc, TransEnterix Inc and Zeltiq Aesthetics Inc. Previously he served as a director of Adams Respiratory Therapeutics Inc, ArgiNOx Pharmaceuticals Inc, Barrier Therapeutics Inc, Bioenvision Inc, Cempra Pharmaceuticals Inc, CardioKine Inc and Myogen Inc. Dr Schiff received his MD from Cornell University Medical College, his MBA from Columbia University, and his BS with honors in Neuroscience from Brown University.

Education